Evotec SE EVT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EVT is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 11.07
- Price/Sales
- 1.16
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 5,055
- Website
- https://www.evotec.com
Competitors
Valuation
|
Metric
|
EVT
|
CTLT
|
CRL
|
|---|---|---|---|
Price/Earnings (Normalized) | 11.07 | 97.40 | 20.66 |
Price/Book Value | 0.82 | 2.78 | 2.96 |
Price/Sales | 1.16 | 2.44 | 2.63 |
Price/Cash Flow | 27.11 | 41.33 | 14.15 |
Price/Earnings
EVT
CTLT
CRL
Financial Strength
|
Metric
|
EVT
|
CTLT
|
CRL
|
|---|---|---|---|
Quick Ratio | 1.65 | 1.56 | 1.17 |
Current Ratio | 1.86 | 2.51 | 1.75 |
Interest Coverage | −6.83 | −4.07 | 4.95 |
Quick Ratio
EVT
CTLT
CRL
Profitability
|
Metric
|
EVT
|
CTLT
|
CRL
|
|---|---|---|---|
Return on Assets (Normalized) | −4.21% | −3.09% | 6.50% |
Return on Equity (Normalized) | −8.08% | −7.79% | 15.17% |
Return on Invested Capital (Normalized) | −5.57% | −0.96% | 9.55% |
Return on Assets
EVT
CTLT
CRL
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| Rhjhlhgjd | Bgrhks | $80.3 Bil | |||
| Zoetis Inc Class A
ZTS
| Ddtyfsbzby | Qzfc | $77.8 Bil | |||
| Haleon PLC ADR
HLN
| Sqynfpdp | Vvs | $37.8 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Cybgxqqq | Zkw | $12.1 Bil | |||
| Viatris Inc
VTRS
| Yxksqlmj | Glhy | $12.1 Bil | |||
| Catalent Inc
CTLT
| Mjgbmnpld | Clyss | $10.0 Bil | |||
| Perrigo Co PLC
PRGO
| Lhylbmtw | Jjhd | $3.7 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Zlhldyp | Nzclpj | $3.2 Bil | |||
| Curaleaf Holdings Inc
CURLF
| Tcwylmyd | Gtfbc | $3.0 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Rbhxqrwhwd | Qdrw | $2.7 Bil |